10592-13-9

• 常用中文名：盐酸多西环素
• 常用英文名：doxycycline hydrochloride
• CAS号：10592-13-9
• 分子式：C₂₂H₂₅ClN₂O₈
• 分子量：480.896
• 相关类别： 生物化工 抑制剂 蛋白酶体(Proteases) MMP 抑制剂
• 发布时间：2018-02-05 08:00:00
• 更新时间：2024-01-02 16:31:05
• Doxycycline盐酸盐是合成的四环素类衍生物,具有抗菌活性。

名称

• 中文名: 盐酸强力霉素
• 英文名: doxycycline HCl
• 中文别名: 强力霉素; 6-甲基-4-(二甲氨基)-3,5,10,12,12a-五羟基-1,11-二氧代-1,4,4a,5,5a,6,11,12a-八氢-2-并四苯甲酰胺盐酸盐; 盐酸多西环素
• 英文别名: Doxylin; samecin; (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride (1:1); (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide hydrochloride; liomycin; EINECS 234-198-7; (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride; Doxycycline (hydrochloride); Doxycycline HCl; tecacin; DOXYCYCLINE; doxycycline hyclate; doxycycline hydrochloride; ecodox; MFCD03427564; 6-deoxy-5-oxytetracycline hydrochloride; novadox; retens; DOXYCYCLINEHCL; HYDRAMYCIN; doxy-ii; a-6-Deoxy-5-hydroxytetracycline Hydrochloride; mespafin; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-, hydrochloride (1:1); (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide hydrochloride (1:1); (4S-(4a,4aa,5a,5aa,6a,12aa))-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride; midoxin

物化性质

• 密度: 1.63 g/cm3
• 沸点: 762.6ºC at 760 mmHg
• 熔点: 195-201℃
• 分子式: C₂₂H₂₅ClN₂O₈
• 分子量: 480.896
• 闪点: 415ºC
• 精确质量: 480.129944
• PSA: 181.62000
• LogP: 1.15470
• 外观性状: 黄色吸湿的结晶粉末
• 储存条件:

  密封于0-6ºC无可用阴凉干燥处。

• 稳定性:

  遵照规格使用和储存则不会分解。

• 水溶解性: H2O: 50 mg/mL, clear, yellow-green
• 分子结构:

  1、摩尔折射率：无可用

  2、 摩尔体积（cm³/mol）： 无可用

  3、 等张比容（90.2K）：无可用

  4、 表面张力（dyne/cm）：无可用

• 计算化学:

  1、 疏水参数计算参考值（XlogP）：无可用

  2、 氢键供体数量：7

  3、 氢键受体数量：10

  4、 可旋转化学键数量：1

  5、 拓扑分子极性表面积（TPSA）：182

  6、 重原子数量：33

  7、 表面电荷：0

  8、 复杂度：956

  9、 同位素原子数量：0

  10、 确定原子立构中心数量：0

  11、 不确定原子立构中心数量：0

  12、 确定化学键立构中心数量：0

  13、 不确定化学键立构中心数量：0

  14、 共价键单元数量：2

• 更多:

  1. 性状：黄色结晶性粉末

  2. 密度（g/mL,25/4℃）： 无可用

  3. 相对蒸汽密度（g/mL,空气=1）：无可用

  4. 熔点（ºC）：无可用

  5. 沸点（ºC,常压）：无可用

  6. 沸点（ºC,5.2kPa）： 无可用

  7. 折射率： 无可用

  8. 闪点（ºC）： 无可用

  9. 比旋光度（º）：无可用

  10. 自燃点或引燃温度（ºC）：无可用

  11. 蒸气压（kPa,25ºC）：无可用

  12. 饱和蒸气压（kPa,60ºC）：无可用

  13. 燃烧热（KJ/mol）：无可用

  14. 临界温度（ºC）：无可用

  15. 临界压力（KPa）：无可用

  16. 油水（辛醇/水）分配系数的对数值：无可用

  17. 爆炸上限（%,V/V）：无可用

  18. 爆炸下限（%,V/V）： 无可用

  19. 溶解性：可溶于水

生物活性

• 描述: Doxycycline盐酸盐是合成的四环素类衍生物,具有抗菌活性。
• 相关类别:
  研究领域 >> 感染
• 靶点:

  MMP

• 体外研究: 强力霉素在体外对鸡毒支原体菌株S6显示出优异的有效性和时间依赖性[2]。与对照成骨细胞培养物相比,在所有实验时间点,暴露于含有25μg/ mL多西环素(DOX)/β-环糊精(βCD)的复合物的成骨细胞具有增加的细胞增殖(p <0.05),在第二周达到最大值。暴露于DOX /βCD复合物的成骨细胞中碱性磷酸酶(AP)活性和胶原分泌水平也升高(与对照相比p <0.05),14天后达到最大值[3]。强力霉素(20 nM)抑制SMC(平滑肌细胞)类型培养物中ECM(细胞外基质)的产生和重塑,SMC-Ch(富含胆固醇的饮食)中胶原蛋白和异戊二烯化蛋白的合成高于SMC -C(标准饮食)[4]。
• 体内研究: 在杂合(HT)Col3a1敲除小鼠中,在用强力霉素或安慰剂治疗3个月后,对9个月大的HT或野生型(WT)小鼠进行主动脉的外科应力。干预后1周未治疗的HT小鼠中应力诱导的主动脉病变增加3倍(累积评分4.5±0.87对比WT中的1.3±0.34,p <0.001)在强力霉素中完全预防(25或100 mg/kg) ,po)-处理组(1.1±0.56)[1]。
• 激酶实验: 将明胶（0.1％（w / v））加入到标准LaemmLi丙烯酰胺聚合混合物中。将组织提取物与样品缓冲液[250mM Tris-Cl pH 6.8,10％（w / v）SDS，20％（v）1：2混合。 / v）甘油，0.005％（w / v）溴酚蓝]。血清用电泳缓冲液（2.5mM Tris，20mM甘氨酸，0.005％SDS）1:10稀释，并与样品缓冲液1：2混合。二十μL是在室温下孵育10分钟而不煮沸。在90V电泳后，将凝胶浸泡在2.5％（w / v）Triton X-100中，在37℃下在明胶消化缓冲液中孵育2至3天[50] mM Tris-Cl，pH 8.0,8mM CaCl 2,10mM ZnSO 2,0.02％（w / v）NaN 3]，在0.05％考马斯蓝R-250的乙酸/甲醇/水（体积比1：4.5：4.5）中染色），在10％乙酸和5％甲醇中脱色，扫描裂解带强度。裂解带强度与明胶酶活性成正比，并用一维扫描软件进行光密度定量。结果，数值在0.07和3.75之间， 没有通过将光密度测定结果与来自BCA蛋白质测定试剂盒结果的相对光密度分开，使蛋白质含量变得均匀。结果用作任意单位的分析。对于MMP-9的裂解条带的总MMP活性结果，加入活性MMP-9，pro-MMP-2和活性MMP-2。蛋白质大小标记用于确定正确的大小。
• 细胞实验: 当SMC中的ECM合成开始明显时，所有体外处理在SMC培养物中以90％汇合进行。将多西环素（20 nM）稀释于培养基中，浓度为10μg/ mL（20 nM），此时未报告原代培养的SMC增殖的毒性或变异，以及其他细胞系，培养时间为48小时将SMC-C和SMC-Ch以相同的细胞密度接种在6孔板中，当汇合度达到90％时，向每个含有3.7×104 Bq L- [5-H3] - 脯氨酸的孔中加入1mL培养基（ 9.62×1011 Bq / mmol）。温育48小时后，将细胞用0.5mL 0.5mol / L NaOH裂解1小时。用等量的0.5mol / L HCl中和所得溶液，用Bradford法测定50μL总蛋白质。向剩余的250μL中加入一体积的10％TCA，并在4℃下以13,000g离心15分钟。将所得沉淀物溶于100μL0.2mol/ L NaOH中，然后用1mol / L HCl中和。将溶液与胶原酶缓冲液（Tris-HCl，pH 7.6 20mM，CaCl 2 250mM终浓度）和10单位胶原酶在37℃温育过夜。然后，加入150μL10％TCA并在4℃下以13000g离心15分钟。将得到的上清液加入到4mL闪烁液中，并在液体闪烁计数器LS 600 TA中测量放射性。
• 动物实验: 用强力霉素治疗两组6个月大的雌性杂合（HT）Col3a1敲除小鼠3个月。用含有200或800mg / kg多西环素的食物提供治疗。因为这些小鼠的初步测量食物摄入量平均为3.5克/天，动物的平均体重为25克，低剂量和高剂量组的平均药物剂量为25（Doxy25）或100（Doxy100）mg /每天kg，分别。未处理的（野生型）WT和HT小鼠维持常规饮食（NIH-07小鼠/大鼠饮食）并用作对照。 3个月后，在一般吸入麻醉（氧气中异氟醚2％）和无菌条件下，腹主动脉通过以下手术进行手术暴露和应激：通过用无菌方法将腹主动脉阻塞在脊柱上来阻止血流。在肾动脉水平压迫棉签。在髂骨分叉处按压第二个涂药器后，第一个涂药器突然松开，然后释放第二个涂药器。缝合腹部切口，将小鼠放回家笼中。干预后继续治疗。干预一周后，通过过量的异氟烷使小鼠安乐死。收集血液，收获主动脉和结肠和皮肤的部分。
• 参考文献:

  [1]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.

  [2]. Zhang N, et al. The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum. Front Microbiol. 2016 May 4;7:653.

  [3]. Trajano VC, et al. Osteogenic activity of cyclodextrin-encapsulated doxycycline in a calcium phosphate PCL and PLGA composite. Mater Sci Eng C Mater Biol Appl. 2016 Jul 1;64:370-5.

  [4]. Palomino-Morales R, et al. Inhibition of extracellular matrix production and remodeling by doxycycline in smooth muscle cells. J Pharmacol Sci. 2016 Mar 25. Epub ahead of print

MSDS

Name: Doxycycline Hydrochloride Material Safety Data Sheet Synonym: Biocamycin; Doxigalumicina; Doxycycline Hyclate; Doxy-II; Midoxin; Novadox; Retens; Tetradox; Vibradox; Hydramycin CAS: 10592-13-9 Section 1 - Chemical Product MSDS Name:Doxycycline Hydrochloride Material Safety Data Sheet Synonym:Biocamycin; Doxigalumicina; Doxycycline Hyclate; Doxy-II; Midoxin; Novadox; Retens; Tetradox; Vibradox; Hydramycin Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 10592-13-9 Doxycycline Hydrochloride ca 100% 234-198-7 Hazard Symbols: XN Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. May cause liver damage. May cause bone structure abnormalities. May be harmful if swallowed. May produce nervous system disturbances. Inhalation: May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Chronic: May cause liver and kidney damage. May cause bone marrow abnormalities with damage to blood forming tissues. Adverse reproductive effects have been reported in animals. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Wash clothing before reuse. Flush skin with plenty of soap and water. Ingestion: Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid. Inhalation: Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask. Notes to Physician: Treat symptomatically and supportively. Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.) Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 10592-13-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: yellow Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not applicable. Flash Point: Not applicable. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Specific Gravity/Density: Molecular Formula: C22H24N2O8HCl Molecular Weight: 480.6366 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable. Conditions to Avoid: Incompatible materials, dust generation, excess heat, strong oxidants. Incompatibilities with Other Materials: Oxidizing agents. Hazardous Decomposition Products: Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide. Hazardous Polymerization: Has not been reported Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 10592-13-9: QI8925000 LD50/LC50: CAS# 10592-13-9: Oral, mouse: LD50 = 1890 mg/kg; Oral, rat: LD50 = 1700 mg/kg. Carcinogenicity: Doxycycline Hydrochloride - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: XN Risk Phrases: Safety Phrases: S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 10592-13-9: 2 Canada CAS# 10592-13-9 is listed on Canada's DSL List. CAS# 10592-13-9 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 10592-13-9 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

毒理学数据: 1 。 试验方法：宫内 摄入剂量： 50毫克/公斤，女性一天（县）前交配 测试对象：啮齿动物-鼠 毒性类型：生殖 毒性作用： 母体效应-子宫，宫颈，阴道 2 。 试验方法：宫内 摄入剂量： 20毫克/千克，女性一天（县）前交配 测试对象：灵长类动物-猴子 毒性类型：生殖 毒性作用： 母体效应-子宫，宫颈，阴道 3 。 试验方法：口服 摄入剂量： 1700毫克/千克 测试对象：啮齿动物-鼠 毒性类型：急性 毒性作用： 1.感官机构和特别感官（眼） -上睑下垂 2.肌肉无力 3.肺，胸部或呼吸-呼吸抑制 4 。 试验方法：腹腔 摄入剂量： 714毫克/千克 测试对象：啮齿动物-鼠 毒性类型：急性 毒性作用： 详细的毒副作用没有报告以外的其他致死剂量值 生态学数据: 该物质对环境可能有危害，对水体应给予特别注意。 CHEMICAL IDENTIFICATION RTECS NUMBER : QI8925000 CHEMICAL NAME : 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride CAS REGISTRY NUMBER : 10592-13-9 LAST UPDATED : 199806 DATA ITEMS CITED : 13 MOLECULAR FORMULA : C22-H24-N2-O8.Cl-H MOLECULAR WEIGHT : 480.94 WISWESSER LINE NOTATION : L E6 C666 BV FV CU GUTTT&J DQ EQ GVZ HQ IN1&1 MQ M1 RQ &GH HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1700 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 8,1447,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 714 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,840,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 700 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 8,1447,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 137 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 8,1447,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1890 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,505,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 179 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,714,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 700 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 8,1447,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 201 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,840,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,714,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,840,1995 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 26 mg/kg/13W-I TOXIC EFFECTS : Cardiac - changes in heart weight Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight REFERENCE : TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 129,214,1994 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 50 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina REFERENCE : CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 29,553,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 20 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina REFERENCE : CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 29,561,1984

安全

• 危害码 (欧洲): Xn: Harmful;Xi: Irritant;
• 风险声明 (欧洲): R22
• 安全声明 (欧洲): 26-36/37
• WGK德国: 3
• 海关编码: 29413000

合成路线

564-25-0 ~92% 10592-13-9

文献：WO2005/112945 A2, ; Page/Page column 117-118 ;

上下游产品

上游产品  1
564-25-0
下游产品  1
564-25-0

海关

海关编码	29413000